# OnCo record gvhd-chronic-overview (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/gvhd-chronic-overview/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "gvhd-chronic-overview" ;
  schema:name "Chronic graft-versus-host disease"@en ;
  schema:alternateName "chronic GvHD"@en, "chronic GVHD"@en, "cGVHD"@en, "cGvHD"@en, "chronic graft versus host disease"@en ;
  schema:description "After a donor transplant the new immune system can treat the body it has landed in as foreign. When that goes on past the first few months it is called chronic graft-versus-host disease, and it affects roughly four in ten adults. It is treatable and often improves, and the same donor immunity also keeps the leukaemia away, so the aim is to control it rather than abolish it."@en ;
  schema:url <https://onco.cc/technologies/gvhd-chronic-overview/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Graft-versus-host_disease> ;
  schema:citation <https://doi.org/10.1016/j.bbmt.2014.12.001>, <https://doi.org/10.3389/frtra.2024.1332181>, <https://doi.org/10.1016/j.bbmt.2014.10.021>, <https://doi.org/10.1016/j.jtct.2023.09.016>, <https://doi.org/10.3324/haematol.2016.150250> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "gvhd", "immune" ;
  onco:related <https://onco.cc/technologies/gvhd-nih-consensus-criteria/>, <https://onco.cc/technologies/gvhd-organ-by-organ/>, <https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/>, <https://onco.cc/technologies/gvhd-prophylaxis/>, <https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/>, <https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/>, <https://onco.cc/technologies/gvhd-photopheresis/>, <https://onco.cc/technologies/rejuv-tx-late-effects-overview/>, <https://onco.cc/technologies/rejuv-tx-what-to-ask-for/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/belumosudil/>, <https://onco.cc/drugs/ibrutinib/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/conditioning-regimen/>, <https://onco.cc/terms/secondary-malignancy/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .